Tempus AI, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. December 16, 2024 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the specified Class Period, which has led to significant investor losses [1][3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Tempus AI securities between August 6, 2024, and May 27, 2025, with a deadline for filing a lead plaintiff motion set for August 12, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation regarding their legal rights and options for recovering losses [2]. Group 2: Allegations Against Tempus AI - The lawsuit alleges that Tempus AI inflated the value of certain contract agreements, many of which involved related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about a joint venture with SoftBank Group Corporation, which allegedly risked credibility by appearing to "round-trip" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is claimed to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risks [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Group 3: Impact on Stock Price - Following the publication of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which highlighted serious concerns regarding Tempus AI's management and operations, the company's stock price fell by over 19% [4].